These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 10717254

  • 1. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N, Marcellin P.
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C, Poovorawan Y, Sura T, Theamboonlers A, Busagorn N, Kurathong S.
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [Abstract] [Full Text] [Related]

  • 5. Therapy of hepatitis C: patients with normal aminotransferase levels.
    Marcellin P, Lévy S, Erlinger S.
    Hepatology; 1997 Sep; 26(3 Suppl 1):133S-136S. PubMed ID: 9305678
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW, Fattovich G, Brouwer JT.
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [Abstract] [Full Text] [Related]

  • 11. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.
    Hepatogastroenterology; 2002 Sep; 49(48):1636-8. PubMed ID: 12397752
    [Abstract] [Full Text] [Related]

  • 12. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A.
    Med Sci Monit; 2000 Sep; 6(5):964-70. PubMed ID: 11208439
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M, Hamada K, Oda Y, Okuno T.
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [Abstract] [Full Text] [Related]

  • 15. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E, Wawrzynowicz-Syczewska M, Jurczyk K, Morańska I, Urbanowicz W, Boroń-Kaczmarska A.
    Wiad Lek; 2005 Feb; 58(11-12):616-21. PubMed ID: 16594470
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.